Plain-English translation of NCT07318558 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Neoplasms research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Researchers are testing a new drug called (sac-TMT) as a maintenance treatment for people with advanced ovarian cancer that does not have certain genetic changes. After you finish your first chemotherapy treatment, this trial will compare whether receiving this medication—with or without another drug called —helps keep your cancer from growing longer than standard care options.
Currently, doctors have limited options to prevent ovarian cancer from coming back after chemotherapy. This trial is designed to see if this new targeted medication can extend the time patients stay cancer-free and live longer than what's available today.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication (given by injection on specific days every 6 weeks), possibly combined with , or standard care (which may include alone or observation only). If you receive the medication, you will get injections multiple times per cycle and continue until your cancer progresses, side effects become too severe, or up to 22 treatment cycles. You will have regular clinic visits and imaging tests to monitor how well the treatment is working.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States